Leiden University Scholarly Publications

Your Search

Enabled Filters

  • (-) = Weinblatt, M.

Refine Results

Resource Type

Availability

Creation Date

Faculty

Collection

Author

Show more

Language

Search results

  • RSS Feed
(1 - 10 of 10)
Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis
Sieberts, S.K.; Zhu, F.; Garcia-Garcia, J.; Stahl, E.; Pratap, A.; Pandey, G.; ... ; Rheumatoid Arth Challenge 2016
Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis
Article / Letter to editor
metadata only
The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016
Winthrop, K.L.; Strand, V.; Heijde, D. van der; Mease, P.; Crow, M.K.; Weinblatt, M.; ... ; Furst, D.E. 2016
The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016
Article / Letter to editor
metadata only
Head-To-Head Comparison of Subcutaneous Abatacept Versus Adalimumab on Background Methotrexate in RA: Blinded Two-Year Results from the AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate) Study
Weinblatt, M.; Schiff, M.; Valente, R.; Heijde, D. van der; Citera, G.; Elegbe, A.; ... ; Fleischmann, R. 2014
Head-To-Head Comparison of Subcutaneous Abatacept Versus Adalimumab on Background Methotrexate in RA: Blinded Two-Year Results from the AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate) Study
Article / Letter to editor
metadata only
X-RAY AND MRI RESULTS FROM A PHASE IIB STUDY OF SUBCUTANEOUS ANTI-INTERLEUKIN-6 MONOCLONAL ANTIBODY CLAZAKIZUMAB WITH OR WITHOUT MTX IN ADULTS WITH MODERATE-TO-SEVERE ACTIVE RA AND INADEQUATE RESPONSE TO CONVENTIONAL DMARDS INCLUDING METHOTREXATE
S. du; Pellas, T.; Heijde, D. van der; Weinblatt, M.; Emery, P.; Zilberstein, M.; Conaghan, P. 2014
X-RAY AND MRI RESULTS FROM A PHASE IIB STUDY OF SUBCUTANEOUS ANTI-INTERLEUKIN-6 MONOCLONAL ANTIBODY CLAZAKIZUMAB WITH OR WITHOUT MTX IN ADULTS WITH MODERATE-TO-SEVERE ACTIVE RA AND INADEQUATE RESPONSE TO CONVENTIONAL DMARDS INCLUDING METHOTREXATE
Article / Letter to editor
metadata only
Oskira-1: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To Methotrexate
Weinblatt, M.; Genovese, M.C.; Ho, M.; Hollis, S.; Rosiak-Jedrychowicz, K.; Kavanaugh, A.; ... ; Heijde, D. van der 2013
Oskira-1: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To Methotrexate
Article / Letter to editor
metadata only
Oskira-3: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To a Tumor Necrosis Factor-alpha Antagonist
Genovese, M.; Heijde, D. van der; Keystone, E.; Spindler, A.; Benhamou, C.L.; Kavanaugh, A.; ... ; Weinblatt, M. 2013
Oskira-3: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To a Tumor Necrosis Factor-alpha Antagonist
Article / Letter to editor
metadata only
Oskira-2: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To Disease-Modifying Antirheumatic Drugs
Dawes, P.; Dimic, A.; Genovese, M.C.; Heijde, D. van der; Jenkins, M.; O'Brien, C.; ... ; Weinblatt, M. 2013
Oskira-2: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To Disease-Modifying Antirheumatic Drugs
Article / Letter to editor
metadata only
Head-to-Head Comparison of Subcutaneous Abatacept Versus Adalimumab in the Treatment of Rheumatoid Arthritis: Key Efficacy and Safety Results from the AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate
Maldonado, M.; Weinblatt, M.; Schiff, M.; Fleischmann, R.; Valente, R.; Heijde, D. van der; ... ; Zhao, C. 2013
Head-to-Head Comparison of Subcutaneous Abatacept Versus Adalimumab in the Treatment of Rheumatoid Arthritis: Key Efficacy and Safety Results from the AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate) Trial
Article / Letter to editor
metadata only
Efficacy and Safety of Certolizumab Pegol in a Broad Population of Patients with Active Rheumatoid Arthritis: Week 28 Results From a Phase IIIb Randomized Controlled Study
Weinblatt, M.; Fleischmann, R.M.; Vollenhoven, R.F. van; Emery, P.; Huizinga, T.W.J.; Cutolo, M.; ... ; Dougados, M. 2011
Efficacy and Safety of Certolizumab Pegol in a Broad Population of Patients with Active Rheumatoid Arthritis: Week 28 Results From a Phase IIIb Randomized Controlled Study
Article / Letter to editor
metadata only
Open-Label Certolizumab Pegol Is Effective In Patients Who Withdrew From Double-Blind Treatment Due To Non-Response
Keystone, E.; Heijde, D. van der; Smolen, J.; Weinblatt, M.; Kvien, T.; Strand, V.; ... ; Combe, B. 2010
Open-Label Certolizumab Pegol Is Effective In Patients Who Withdrew From Double-Blind Treatment Due To Non-Response
Other
metadata only